Anika E. Adeni

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

Esther Aguilar, Biagio Ricciuti, Justin F. Gainor et al. · Annals of Oncology · 2019 · 336 citations

Medicine, Oncology, Pharmacology +17

Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications

Biagio Ricciuti, Suzanne E. Dahlberg, Anika E. Adeni et al. · Journal of Clinical Oncology · 2019 · 320 citations

Medicine, Immunology, Oncology +15

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses

Israel Cañadas, Rohit Thummalapalli, Jong Wook Kim et al. · Nature Medicine · 2018 · 317 citations · Full text

Life Sciences, Immunology, Oncology +14

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC

Alissa Keegan, Biagio Ricciuti, Padric M. Garden et al. · Journal for ImmunoTherapy of Cancer · 2020 · 158 citations · Full text

Medicine, Immunology, Oncology +17

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non–Small-Cell Lung Cancer

Natalie I. Vokes, David Liu, Biagio Ricciuti et al. · JCO Precision Oncology · 2019 · 120 citations · Full text

Medicine, Immunology, Oncology +17